puxitatug samrotecan
Sponsor Astrazeneca PLC · listed as AZN
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
puxitatug samrotecan is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 15, 2027 (day precision, medium confidence), tied to trial NCT07044336. The asset is in Phase 3 and currently recruiting, studied in Endometrial Cancer.
Next catalyst
Event typeREADOUT
Expected date2027-10-15
As disclosedOct 15, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT07044336
PhasePHASE3
StatusRECRUITING
Lead sponsorAstraZeneca
Listed asAZN
Condition(s)Endometrial Cancer; Malignant Solid Tumour
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More AZN catalysts